Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Olaparib Monotherapy or Combination Therapy in Lung Cancer: An Updated Systematic Review and Meta- Analysis Publisher



Hajihosseini S1 ; Emami E1 ; Zakavi SA2 ; Jochin P3 ; Shahrokhi M3 ; Khoshravesh S4 ; Goli M5 ; Belbasi M6 ; Erabi G7 ; Deravi N8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Students Research Committee, School Of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
  3. 3. School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  4. 4. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. 5. Department of Medical-Surgical Nursing, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  6. 6. Students Research Committee, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran
  7. 7. Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran
  8. 8. Student Research Committee, Shahid Beheshti University of Medical Science, Tehran, Iran

Source: Frontiers in Oncology Published:2025


Abstract

Background and aims: Impaired double strand DNA repair by homologous repair deficiency (HRD) leads to sensitivity to poly ADP ribose polymerase (PARP) inhibition. A subset of non-small cell lung cancers (NSCLCs) harbour impaired DNA double strand break repair. This study aims to investigate meta-analysis on the olaparib monotherapy or combination therapy in lung cancer. Methods: A comprehensive search was conducted in Pubmed, Scopus and Google Scholar data bases up to August 13, 2023 related articles were extracted title, abstract and full text of articles were screened. The quality included articles were assessing the data was extracted and hence analysis. Results: After screening 5208 articles, 9 were selected for final review based on relevance to the topic. Olaparib monotherapy increased progression free survival (PFS) level [ES= 7.76; 95% CI= 0.16 to 1.36; P=0.208]. Olaparib maintenance therapy increased PFS compared to placebo in platinum-sensitive NSCLC patients [ES= 0.9; 95% CI= 0.9 to 0.9]. Combination therapy with durvalumab and olaparib decreased PFS level compared to the olaparib group [ES=6.07; 95% confidence interval (95% CI) = 0.67 to 11.46; P=0.000]. Adding gefitinib to olaparib decreased PFS compared to olaparib only group, significantly (ES=3.39; 95% CI=-0.78 to 7.56; P=0.609). Conclusions: Our study demonstrated olaparib as monotherapy can increase the PFS of patients with lung cancer, but the combination of olaparib and gefitinib or the combination of olaparib plus durvalumab couldn’t have a significant effect. According to the high heterogeneous rate of studies further large-scale randomized control trials are still required to progress association. Systematic Review Registration: Open Science Framework (OSF). Copyright © 2025 Hajihosseini, Emami, Zakavi, Jochin, Shahrokhi, Khoshravesh, Goli, Belbasi, Erabi and Deravi.